THOMAS OSINOWO: Open Payments
NPI 1518044585 · MONROE, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,089 in 47 payments from 13 companies in 2025. Trend: 2023 $563 · 2024 $466 · 2025 $1,089
Food & beverage: $1,089
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 7 | $254 |
| ABBVIE INC. | 10 | $253 |
| E.R. Squibb & Sons, L.L.C. | 11 | $156 |
| Vanda Pharmaceuticals Inc. | 3 | $73 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $72 |
| Otsuka America Pharmaceutical, Inc. | 3 | $67 |
| Alkermes, Inc. | 2 | $48 |
| Teva Pharmaceuticals USA, Inc. | 2 | $36 |
| Lundbeck LLC | 2 | $34 |
| Axsome Therapeutics, Inc. | 1 | $29 |
Products named: INGREZZA, VRAYLAR, COBENFY, HETLIOZ, CAPLYTA, REXULTI, ARISTADA, ABILIFY MAINTENA.
Industry payments across MI — which companies pay providers there.
